About: The effects of ARBs, ACEIs and statins on clinical outcomes of COVID-19 infection among nursing home residents

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The effects of ARBs, ACEIs and statins on clinical outcomes of COVID-19 infection among nursing home residents Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The effects of ARBs, ACEIs and statins on clinical outcomes of COVID-19 infection among nursing home residents
Creator	Fedson, David Dijck, Van Bean, Belmans, Luc Bronselaer, Antoon Byttebier, Geert De Spiegeleer, Anton De Spiegeleer, Bart De Tré, Guy Dobson, Richard Teo, James Van De Wiele, Christophe Vandaele, Filip Wynendaele, Evelien
Source	MedRxiv
abstract	Background. COVID-19 infection has limited preventive or therapeutic drug options at this stage. Some of common existing drugs like angiotensin-converting enzyme inhibitors (ACEi), angiotensin II receptor blockers (ARB) and the HMG-CoA reductase inhibitors (statins) have been hypothesised to impact on disease severity. However, up till now, no studies investigating this association were conducted in the most vulnerable and affected population groups, i.e. older people residing in nursing homes. The purpose of this study has been to explore the association of ACEi/ARB and/or statins with clinical manifestations in COVID-19 infected older people residing in nursing homes. Methods and Findings. We undertook a retrospective multi-centre cohort study in two Belgian nursing homes that experienced similar COVID-19 outbreaks. COVID-19 diagnoses were based on clinical suspicion and/or viral presence using PCR of nasopharyngeal samples. A total of 154 COVID-19 positive subjects was identified. The outcomes were defined as 1) serious COVID-19 defined as a long-stay hospital admission (length of stay [≥] 7 days) or death (at hospital or nursing home) within 14 days of disease onset, and 2) asymptomatic, i.e. no disease symptoms in the whole study-period while still being PCR diagnosed. Disease symptoms were defined as any COVID-19-related clinical symptom (e.g. coughing, dyspnoea, sore throat) or sign (low oxygen saturation and fever) for [≥] 2 days out of 3 consecutive days. Logistic regression models with Firth corrections were applied on these 154 subjects to analyse the association between ACEi/ARB and/or statin use with the outcomes. Age, sex, functional status, diabetes and hypertension were used as covariates. Sensitivity analyses were conducted to evaluate the robustness of our statistical significant findings. We found a statistically significant association between statin intake and the absence of symptoms during COVID-19 infection (unadjusted OR 2.91; CI 1.27-6.71; p=0.011), which remained statistically significant after adjusting for age, sex, functional status, diabetes mellitus and hypertension. The strength of this association was considerable and clinically important. Although the effects of statin intake on serious clinical outcome (long-stay hospitalisation or death) were in the same beneficial direction, these were not statistically significant (OR 0.75; CI 0.25-1.85; p=0.556). There was also no statistically significant association between ACEi/ARB and asymptomatic status (OR 1.52; CI 0.62-3.50; p=0.339) or serious clinical outcome (OR 0.79; CI 0.26-1.95; p=0.629). Conclusions. Our data indicate that statin intake in old, frail people could be associated with a considerable beneficial effect on COVID-19 related clinical symptoms. The role of statins and any interaction with renin-angiotensin system drugs need to be further explored in larger observational studies as well as randomised clinical trials.
has issue date	2020-05-15(xsd:dateTime)
bibo:doi	10.1101/2020.05.11.20096347
has license	medrxiv
sha1sum (hex)	284d29e372b4cdb024f703e514666d7b19153797
schema:url	https://doi.org/10.1101/2020.05.11.20096347
resource representing a document's title	The effects of ARBs, ACEIs and statins on clinical outcomes of COVID-19 infection among nursing home residents
resource representing a document's body	covid:284d29e372b4cdb024f703e514666d7b19153797#body_text
is schema:about of	named entity 'residing' named entity 'drugs' named entity 'angiotensin-converting enzyme inhibitors' named entity 'suspicion' named entity 'BASED' named entity 'DISEASE SEVERITY' named entity 'SIMILAR' named entity 'POSITIVE' named entity 'SAMPLES' named entity 'LIKE' named entity 'DIAGNOSES' named entity 'RETROSPECTIVE' named entity 'COMMON' named entity 'HMG-CoA reductase' named entity 'Some' named entity 'groups' named entity 'blockers' named entity 'preventive' named entity 'existing' named entity 'based' named entity 'PCR' named entity 'inhibitors' named entity 'COVID-19' named entity 'nursing homes' named entity 'COVID-19' named entity 'nasopharyngeal' named entity 'statins' named entity 'ACEi' named entity 'COVID' named entity 'infection' named entity 'COVID' named entity 'medRxiv' named entity 'hypertension' named entity 'ARDS' named entity 'medRxiv' named entity 'fever' named entity 'statins' named entity 'statistical significance' named entity 'statin' named entity 'COVID' named entity 'oxygen saturation' named entity 'ACEi' named entity 'statistically significant' named entity 'COVID' named entity 'statins' named entity 'runny nose' named entity 'sampling' named entity 'endothelial' named entity 'relational database' named entity 'nursing home' named entity 'nursing homes' named entity 'statistically significant' named entity 'COVID' named entity 'general physician' named entity 'statins' named entity 'angiotensin' named entity 'transcription of genes' named entity 'functional status' named entity 'telmisartan' named entity 'nasopharyngeal' named entity 'hypercoagulability' named entity 'ACEi' named entity 'ARBs' named entity 'dependent and independent variables' named entity 'vascular permeability' named entity 'PCR' named entity 'nursing homes' named entity 'statin' named entity 'coagulopathy' named entity 'statin' named entity 'Ang II' named entity 'ACEi'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software